Glenmark Pharma signs $18 mn deal with Hengrui for cancer therapy drug (Soban News)

The agreement gives Glenmark exclusive rights to develop and commercialise cancer drug Trastuzumab Rezetecan outside China, the US, Europe, and other select markets​The agreement gives Glenmark exclusive rights to develop and commercialise cancer drug Trastuzumab Rezetecan outside China, the US, Europe, and other select markets ​Latest News [ SOBAN NEWS: International and National ]